Introduction

Gene editing technologies, particularly CRISPR-Cas9, have emerged as transformative tools in medicine. Among the most promising applications is the creation of universal donor blood — red blood cells that can be safely transfused into any patient regardless of ABO or Rh type. Achieving this would address persistent shortages, reduce transfusion reactions, and simplify blood bank logistics worldwide. While still experimental, recent advances bring us closer to a reality where a single unit of blood could serve patients of all blood types.

Understanding Blood Types and Their Clinical Implications

Human blood is classified by the presence or absence of specific antigens on the surface of red blood cells. The two most clinically significant systems are the ABO group and the Rh factor. The ABO system includes four main types — A, B, AB, and O — determined by whether A and/or B antigens are present. Type O lacks both A and B antigens but carries anti-A and anti-B antibodies in plasma. The Rh system is defined by the presence (Rh-positive) or absence (Rh-negative) of the D antigen.

Compatibility between donor and recipient is essential to prevent life-threatening transfusion reactions. If a recipient’s immune system encounters mismatched antigens, pre-existing antibodies can trigger hemolysis, fever, or anaphylaxis. For example, a person with type A blood cannot receive type B blood. Similarly, an Rh-negative patient transfused with Rh-positive cells may develop anti-D antibodies, causing complications in future pregnancies or transfusions.

This compatibility requirement forces blood banks to maintain adequate inventories of each type. Type O negative blood — the “universal donor” for red cells because it carries no A, B, or RhD antigens — can be given to anyone. However, only about 7% of the population has O negative blood, leading to chronic shortages. In emergencies, hospitals often face critical delays while matching blood types, and patients with rare blood types may struggle to find compatible units.

The Global Burden of Blood Shortages

The World Health Organization reports that many low- and middle-income countries lack sufficient safe blood supplies. Even in developed nations, seasonal shortages and surges in demand require careful management. Transfusion errors, though rare, still occur and can be fatal. A universal donor blood product would eliminate crossmatching requirements, allow immediate transfusion in trauma, and significantly reduce the risk of ABO incompatibility.

Current Approaches to Creating Universal Blood and Their Limitations

Before gene editing, scientists attempted to convert blood types using enzymes that cleave antigenic sugars from red blood cells. For instance, researchers have used specific glycosidases to remove A and B antigens, converting type A or B blood into type O. This enzymatic conversion has been tested in clinical trials with mixed success. The process is inefficient, expensive, and sometimes damages the red cell membrane, reducing cell survival after transfusion. Moreover, it does not address the Rh factor.

Another avenue is the development of synthetic blood substitutes, such as perfluorocarbon emulsions or hemoglobin-based oxygen carriers. These products have faced safety concerns and limited efficacy. They do not mimic all functions of red blood cells, lack clotting factors, and have not replaced human blood for routine transfusion. Thus, the search for a scalable, safe universal blood remains a high priority.

Gene editing offers a fundamentally different approach: instead of modifying an existing blood product, it permanently alters the genetic blueprint of red blood cell precursors to eliminate immunogenic antigens at the source.

Gene Editing: The Methodologies Behind Universal Donor Blood

CRISPR-Cas9 is the most widely used tool for targeted gene knockout. It consists of a guide RNA that directs the Cas9 nuclease to a specific genomic sequence, creating a double-strand break that the cell repairs through non-homologous end joining, often disrupting the gene. For universal donor blood, researchers target the genes responsible for adding A and B antigens (the ABO locus) and the RHD gene that encodes the RhD antigen.

Early proof-of-concept studies have shown that CRISPR-Cas9 can efficiently knockout these genes in hematopoietic stem cells (HSCs) or in erythroid precursor cells. The edited cells can then be cultured to produce red blood cells devoid of the targeted antigens. These engineered red cells behave normally in laboratory assays and resist binding by antibodies against the removed antigens.

Targeting the ABO Locus

The ABO gene encodes a glycosyltransferase that attaches either N-acetylgalactosamine (type A) or galactose (type B) to a precursor oligosaccharide called H antigen. Individuals with type O blood have a non-functional ABO enzyme, leaving the H antigen unmodified. By knocking out the ABO gene in cells from type A or B donors, researchers can produce red cells with only the H antigen, functionally equivalent to type O. This approach avoids the need for donor selection or enzymatic conversion.

Addressing the Rh Factor

The RHD gene encodes the RhD protein, which sits on the red cell membrane. If absent, the cell is Rh-negative. Knocking out RHD in HSCs from Rh-positive donors yields Rh-negative red cells. Combining ABO knockout and RHD knockout in the same cell line could produce O negative cells — the universal donor. Several groups have demonstrated dual gene editing in human HSCs with high efficiency, though challenges remain in ensuring the edited cells retain their ability to produce functional red blood cells.

Safety and Functional Integrity

Gene editing must not compromise the red cell’s oxygen-carrying capacity, deformability, or lifespan. Off-target effects, where Cas9 cuts unintended genomic sites, could lead to mutations that affect cell health or even cause cancer. Rigorous quality control includes whole-genome sequencing, functional assays (e.g., osmotic fragility, hemoglobin oxygen affinity), and in vivo survival studies in mouse models. Early results suggest that edited red cells have normal morphology and function, but long-term studies are needed.

Another safety consideration is the potential for immunogenicity of the Cas9 protein itself. Some individuals have pre-existing antibodies against Cas9 from common bacterial infections. Using modified Cas9 variants or transient delivery methods can reduce immune responses. Additionally, eliminating residual undifferentiated cells in the final product is critical to prevent teratoma formation if iPSCs are used as the cell source.

Preclinical and Clinical Progress

Several research teams have published compelling preclinical data. In 2019, scientists at the University of British Columbia used CRISPR to convert type A blood to type O in vitro, achieving 99% removal of A antigens. More recently, a group in Denmark demonstrated successful knockout of both ABO and RHD in hematopoietic stem cells with subsequent differentiation into red blood cells that passed compatibility testing.

Human clinical trials have not yet begun, but the path forward is being mapped. One major challenge is scaling production. A single transfusion unit contains about 2×10¹² red blood cells. Producing that many edited cells in culture requires bioreactor optimization, efficient gene editing with minimal toxicity, and cost-effective manufacturing. Another challenge is the longevity of edited cells: naturally circulating red cells last about 120 days, but cultured red cells often have shorter lifespans. Researchers are working to improve maturation protocols.

Induced pluripotent stem cells (iPSCs) offer an alternative source. iPSCs can be expanded indefinitely, edited with CRISPR, and then differentiated into red blood cells. This approach could provide an unlimited, standardized universal donor product. However, the differentiation process is still inefficient and expensive. Several biotech companies are investing in this technology, aiming to reach clinical trials within the next 5–10 years.

Potential Benefits for Transfusion Medicine

Universal donor blood would transform transfusion practice. Hospitals could stock a single product for emergency transfusion, eliminating the need to wait for type-specific units. In disasters or military conflicts where blood supply is limited, a universal product would save lives by simplifying logistics.

Blood banks would no longer need to discard outdated units of rare types due to low demand. The production of O negative blood from common donors (type A or B) could dramatically increase the supply of this scarce resource. According to the American Red Cross, type O negative units are often at critical levels; gene editing could help stabilize inventories.

For patients with autoimmune hemolytic anemia or those who require chronic transfusion (e.g., sickle cell disease, thalassemia), universal donor blood would reduce the risk of alloimmunization — the development of antibodies against minor antigens. While gene editing primarily targets major antigens, additional modifications could eliminate other immunogenic proteins (e.g., Kell, Duffy) to create an even safer product.

From a global health perspective, universal donor blood would lower the barrier for safe transfusion in developing countries that lack robust blood typing infrastructure. The World Health Organization estimates that 42% of donated blood in low-income countries is not screened properly; a universal product would inherently be safe for any recipient, simplifying distribution and reducing errors.

Ethical and Regulatory Considerations

As with any gene therapy, creating universal donor blood raises ethical questions. The editing is performed on somatic cells (HSCs or iPSCs), not on embryos, so germline modification concerns do not apply. However, ensuring informed consent from donors of starting material is critical, especially if immortalized iPSC lines are used that could be distributed globally.

Regulatory frameworks for cell and gene therapies are still evolving. In the United States, the FDA would likely regulate these products as biologics or cell-based therapies, requiring investigational new drug applications. In Europe, the European Medicines Agency has guidelines for genetically modified cells. Key requirements include demonstration of purity, potency, and safety — including long-term follow-up for recipients to monitor for unexpected immune reactions or malignant transformation.

Cost is another ethical dimension. Gene-edited universal donor blood will likely be expensive initially, potentially exacerbating global health inequities. Policymakers and industry must work to ensure affordable access, perhaps through tiered pricing or licensing arrangements for low-resource settings. Public funding for research can also help de-risk development and reduce eventual costs.

Future Outlook and Remaining Challenges

The path from laboratory to bedside requires solving several hurdles. Efficiency of gene editing must exceed 90% to avoid contaminating the final product with antigen-positive cells. With current methods, efficiency is closer to 70–80% for dual knockout, but improvements in CRISPR delivery (e.g., lipid nanoparticles, electroporation) are accelerating progress.

Large-scale biomanufacturing of red blood cells from edited stem cells remains a formidable task. Bioreactor systems that mimic bone marrow conditions — including specific oxygen gradients, shear stress, and cellular niches — are under development. Companies like Biopharma and other academic groups have produced small volumes of cultured red cells for transfusion in clinical trials (e.g., the REDS study). Scaling to commercial volumes will require significant engineering innovation.

Another avenue is ex vivo gene editing of donated whole blood units. Instead of growing cells from scratch, researchers could directly edit the red cells in a standard unit of blood using viral or non-viral vectors. This would leverage existing blood bank infrastructure, but the editing efficiency in mature red cells (which lack a nucleus) is limited; the approach would need to target the reticulocyte stage or use alternative methods to modify surface antigens without DNA editing.

Despite these hurdles, the potential impact justifies the investment. In 2023, the global blood transfusion market was valued at over $30 billion, with consistent growth. A safe, effective universal donor product could capture a significant share and improve clinical outcomes for millions of patients each year.

Conclusion

Gene editing offers a powerful route to universal donor blood, addressing a long-standing challenge in transfusion medicine. By eliminating ABO and Rh antigens at the genetic level, researchers can create red blood cells compatible with any recipient, reducing shortages, preventing errors, and simplifying logistics. While still in preclinical development, progress in CRISPR technology and stem cell culture brings this goal into view. Continued investment in efficiency, safety, and scalable manufacturing — coupled with thoughtful regulatory and ethical oversight — can turn this promise into a life-saving reality for patients worldwide.